Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 February 2018 Photo Facebook
Louzanne and Marné included in national student cross country teams
Athlete Louzanne Coetzee, and her guide, Xavier Adams

Two Kovsie athletes, including the blind athlete and world record holder, Louzanne Coetzee, have been included in the national student cross country team.

Coetzee and Marné Mentz will compete at the World Student Cross Country championship on 7 April in St Gallen in Switzerland.

They qualified for the team after good performances at the Athletics South Africa’s cross country trials held at the University of the Free State (UFS) on 20 January. The distance was over 10km.

What makes Coetzee’s inclusion even more remarkable is the fact that she will be competing against able-bodied runners. The world record holder in the 5 000m in her disability category (T-11) and her new guide, Xavier Adams, finished first among the female students in a time of 39:32, which is her personal best. Mentz ended in second place for students in 39:44. They will make up two of the six spots in the women’s team in Switzerland.

First for Coetzee

It is the first time that Coetzee was chosen for an able-bodied national team. She is doing a master’s degree in Reconciliation and Social Cohesion this year and Mentz is in her final year of a BEd Intermediate Phase.

Tshepang Sello, another Kovsie and an Olympic athlete from Lesotho, took first position for students in 38:04 but did not qualify for the South African team because of her Lesotho citizenship.

Kesa Molotsane (35:29) was the overall winner. Although Molotsane is still doing her honours this year, she ran in the open division as she no longer qualifies as a student because she is over the age of 25, according to University Sport South Africa regulations.

Molotsane ,26, is the national cross country champion of 2016 and obtained second spot last year.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept